Wegovy Alternatives: Compounded Semaglutide, Zepbound, and Ozempic, Compared

Is there a generic version of Wegovy?

Semaglutide is the generic name for Wegovy — the chemical name printed on the label, the same molecule sold under Ozempic and Rybelsus, and the word that surfaces whenever someone searches "wegovy generic brand" hoping for a cheaper substitute. That's worth separating from what people actually mean by the question, because the honest answer to "is there a generic Wegovy" is no — not a lower-cost, generic-manufacturer version a pharmacist can hand you instead of the brand.

It isn't for lack of trying. Novo Nordisk's core patent on semaglutide as a molecule — the composition-of-matter patent that matters most for a true generic — runs out around 2032 in the US, and a related patent covering the specific dosage regimens used to treat diabetes and obesity, granted in 2019, extends protection to 2033. Starting in 2022, a string of generic manufacturers — Alvogen first, followed by Rio Biopharmaceuticals, Sun Pharmaceutical, Dr. Reddy's, Mylan (a Viatris subsidiary), Zydus, and Apotex — filed abbreviated new drug applications and challenged those patents under the standard process that lets a generic maker contest a brand's patent before it expires. That's what triggered Novo Nordisk's own infringement lawsuit against Alvogen in Delaware in March 2022, and the related cases were eventually folded into a single proceeding, In re: Ozempic (Semaglutide) Patent Litigation. Viatris separately asked the US Patent and Trademark Office to invalidate the underlying patents outright — a request the review board rejected for two of the patents but agreed to take up for the dosage-regimen patent specifically.

None of that produced a generic on a shelf. Through 2024, Novo Nordisk settled with essentially every one of those challengers rather than litigating to a verdict, and — standard for this kind of settlement — the terms, including whatever entry date each generic maker actually agreed to, are confidential and subject to review by the FTC and Department of Justice for anticompetitive terms. So real applications were filed, real litigation happened over two years, and it's genuinely resolved between the companies involved — it just doesn't tell the public when, or whether, an FDA-approved generic semaglutide product reaches a US pharmacy. With the underlying patents running to 2032 and 2033, independent industry analysts generally don't expect that before the early-to-mid 2030s at the earliest.

One thing that muddies this online: semaglutide's patent protection has already started expiring in some other countries in 2026 — India specifically, where dozens of manufacturers have moved to launch their own versions — which is why "generic semaglutide" headlines are circulating right now. None of that changes the separately litigated and settled US timeline above. If you're holding out for a generic before treating Wegovy's cost as a solvable problem today, the honest answer is: not this year, and not with a confirmed date for next year either.

Wegovy is out of stock or my insurance won't cover it — now what?

Start by separating a national shortage from a local one, because they're no longer the same problem. The FDA declared Wegovy's shortage resolved on February 21, 2025, and by 2026 supply nationally is sufficient to meet demand — but that's an aggregate figure, not a guarantee your specific pharmacy has your specific dose in stock this week. A dose-level stockout at one location is worth solving by checking NovoCare's own pharmacy network or a different retail location, not a reason to assume the drug itself has become unavailable nationally.

If it's insurance rather than supply, the fastest real move is usually an appeal backed by your prescriber's documentation of BMI and any qualifying condition — a meaningful share of initial denials reverse on the first appeal. Wegovy cost walks through the full insurance, savings-card, and Medicare pathway in more depth if you haven't ruled all of them out yet. If none of that resolves it, the rest of this page covers what genuinely replaces Wegovy when the brand itself isn't the answer right now.

Compounded semaglutide: the closest real substitute

If Wegovy specifically is the obstacle and semaglutide the molecule is still the goal, compounded semaglutide is the closest thing to a real substitute — because it isn't really a substitute at all, it's the same active ingredient, prepared by a licensed 503A pharmacy for a named patient rather than manufactured by Novo Nordisk as an FDA-approved finished drug. It runs roughly $149 to $300 a month all-in at a reputable provider, well under Wegovy's own retail price, and it's legal only under a narrower exception than a couple of years ago — a prescriber has to document a real clinical reason the commercial product doesn't meet, since cost savings alone stopped qualifying once the FDA declared the shortage resolved. For the full five-provider price comparison and the legal detail worth understanding before you enroll, see what a Wegovy compounding pharmacy actually sells rather than a shortened version of that table here.

Switching from Wegovy to Zepbound (or the reverse) — is it worth it?

Zepbound is a real alternative, not a knockoff, and also not an automatic upgrade — worth being honest about both halves of that. Tirzepatide, Zepbound's active ingredient, produced a bigger average result than semaglutide in SURMOUNT-5, the first trial to test the two molecules head-to-head — though Wegovy's newer 7.2mg HD dose has since narrowed that gap, not closed it. Zepbound starts around $299 a month self-pay through LillyDirect. What you'd be giving up is Wegovy's lower price at nearly every comparable tier and its once-daily pill option, which Zepbound doesn't have at all. Whether that trade is worth it comes down to how much of the SURMOUNT-5 gap matters to you against the extra cost — not a universal answer either direction. The full trial verdict, current pricing on both drugs, and how a real clinical switch works is covered in Wegovy vs. Zepbound, not repeated here.

What about Ozempic — can I just get that instead, cheaper?

Only with a catch worth knowing before you ask your prescriber. Ozempic is the same molecule, semaglutide, made by the same company — but it's FDA-approved only for type 2 diabetes, and both its manufacturer savings card and its easiest insurance path require a prescription that actually matches that label. Without a diabetes diagnosis, Ozempic isn't automatically cheaper than Wegovy; at the self-pay tier the two brands land close to each other, and Wegovy's own savings card is actually the easier $25-a-month route off a weight-management diagnosis alone. Ozempic vs. Wegovy has the full pricing and eligibility breakdown.

Wegovy over the counter: are the cheap "semaglutide" pills, patches, or gummies real?

No — and the enforcement risk here has widened past just the product itself. In July 2025, the FTC settled with Southern Health Solutions, doing business as NextMed, a telehealth weight-loss membership company the agency accused of using fabricated before-and-after photos, paid and pressured reviews, and a headline membership fee that hid the real cost of medication, consultations, and labs behind it. The FTC's own case summary names GLP-1 weight-loss marketing specifically, not a fake pill — a different failure mode than the usual scam: a real prescription category sold through a deceptive funnel, not just an inert product pretending to be one.

The more familiar version is still worth naming plainly. No over-the-counter patch, pill, or gummy marketed with "semaglutide" or "GLP-1" in its name actually contains the drug. Semaglutide is a prescription-only peptide that requires a clinical consult and a licensed pharmacy to dispense — a product sold with neither, on a checkout page or a social ad, isn't semaglutide no matter what the label implies.

So which Wegovy alternative actually makes sense for you?

• Your insurance already covers Wegovy: the NovoCare savings card at ~$25/mo beats every alternative on this page — confirm coverage before shopping elsewhere.
• Wegovy is unaffordable and you want to stay on the identical molecule: compounded semaglutide through a provider like Curex is the closest real substitute, at roughly $149-$300/mo — understand the narrower legal footing first.
• You want the strongest average result and cost is secondary: Zepbound has the only true head-to-head trial win over semaglutide, at a real cost premium.
• You have a documented type 2 diabetes diagnosis: ask specifically about Ozempic and its savings card — a weight-loss-only prescription won't unlock it.
• Your specific pharmacy is out of stock, not the drug nationally: check NovoCare's own network or another retail pharmacy before assuming Wegovy itself is unavailable.
• You're tempted by a cheap OTC "semaglutide" pill, patch, or gummy: skip it — treat the savings as illusory, since none of them are the real molecule.

Annual cost math across every real alternative

• Wegovy, insured + NovoCare savings card: about $300/yr ($25/mo) — see Wegovy cost.
• Wegovy, Medicare GLP-1 Bridge: about $600/yr ($50/mo) — see Wegovy cost.
• Compounded semaglutide, Curex starter rate: about $1,788/yr (from $149/mo) — see what a Wegovy compounding pharmacy actually sells.
• Wegovy, NovoCare self-pay pill at top dose: about $3,588/yr ($299/mo) — see Wegovy cost.
• Wegovy, NovoCare self-pay pen at maintenance: about $4,188/yr ($349/mo) — see Wegovy cost.
• Zepbound, insured + savings card: about $300/yr ($25/mo) — see Wegovy vs. Zepbound.
• Zepbound, LillyDirect self-pay at maintenance: about $5,388/yr ($449/mo) — see Wegovy vs. Zepbound.
• Ozempic, insured + savings card (T2D diagnosis only): about $300/yr ($25/mo) — see Ozempic vs. Wegovy.
• Wegovy, retail with no program: roughly $16,200/yr (~$1,350/mo) — the figure every pathway above exists to beat.